- Home
- SATL vs MBX Comparison
SATL vs MBX Comparison
Compare SATL & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- MBX
- Stock Information
- Founded
- SATL 2010
- MBX 2018
- Country
- SATL United States
- MBX United States
- Employees
- SATL N/A
- MBX N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- MBX
- Sector
- SATL Technology
- MBX
- Exchange
- SATL Nasdaq
- MBX NYSE
- Market Cap
- SATL 433.8M
- MBX 379.7M
- IPO Year
- SATL N/A
- MBX 2024
- Fundamental
- Price
- SATL $3.58
- MBX $12.47
- Analyst Decision
- SATL
- MBX Strong Buy
- Analyst Count
- SATL 0
- MBX 5
- Target Price
- SATL N/A
- MBX $37.40
- AVG Volume (30 Days)
- SATL 1.8M
- MBX 323.8K
- Earning Date
- SATL 08-14-2025
- MBX 08-16-2025
- Dividend Yield
- SATL N/A
- MBX N/A
- EPS Growth
- SATL N/A
- MBX N/A
- EPS
- SATL N/A
- MBX N/A
- Revenue
- SATL $12,929,000.00
- MBX N/A
- Revenue This Year
- SATL N/A
- MBX N/A
- Revenue Next Year
- SATL N/A
- MBX N/A
- P/E Ratio
- SATL N/A
- MBX N/A
- Revenue Growth
- SATL 9.47
- MBX N/A
- 52 Week Low
- SATL $0.72
- MBX $4.81
- 52 Week High
- SATL $5.49
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- SATL 48.56
- MBX N/A
- Support Level
- SATL $3.43
- MBX N/A
- Resistance Level
- SATL $3.93
- MBX N/A
- Average True Range (ATR)
- SATL 0.21
- MBX 0.00
- MACD
- SATL 0.02
- MBX 0.00
- Stochastic Oscillator
- SATL 54.32
- MBX 0.00
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.